PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
Pharma & Biotech
Pharma & Biotech
Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy
Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.
Pharma & Biotech
Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test
MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.
Pharma & Biotech
Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma
Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.
Pharma & Biotech
Turn Therapeutics moves to refine GX-03 as the atopic dermatitis evidence bar rises
Explore how Turn Therapeutics is refining the GX-03 Phase 2 trial after rapid eczema responses and a strong vehicle effect. Read what comes next.
Pharma & Biotech
Can Vertex turn its $10bn Crinetics deal into a rare endocrinology powerhouse?
Discover why Vertex is paying $10 billion for Crinetics and how Palsonify and atumelnant could reshape rare endocrine treatment.
Pharma & Biotech
Ascletis advances once-monthly ASC36 and ASC36_35 obesity injections into FDA review
Discover why Ascletis’ monthly ASC36 and ASC36_35 obesity drugs matter, and which clinical risks could determine their future.
Pharma & Biotech
Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment
See how Brii Bio’s Phase 2b hepatitis B data support BRII-179 immune priming while durability and Phase 3 risks remain.
Pharma & Biotech
Why Permeasis MTD4 could reshape enzyme replacement and intracellular drug discovery
Discover how Permeasis Therapeutics’ MTD4 platform delivers functional proteins inside cells, and the risks that remain before clinical testing.